Plus Therapeutics, Inc. (PSTV) Stock

Plus Therapeutics, Inc. (PSTV) is a Healthcare stock trading at $4.21 (as of 2026-06-18), with a market capitalization of $17.11M and a trailing P/E of -38.8. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing, manufacturing, and commercializing therapies for cancer and other diseases, including treatments for central nervous system tumors. Its lead candidate is Rhenium-186 NanoLiposome, a radiotherapy being developed for conditions such as recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers, and it also has a license agreement with NanoTx, Corp. for glioblastoma-related development and commercialization.

Valuation — source: SEC EDGAR (first-party)
Price	$4.21
Market Cap	$17.11M
P/E Ratio	-38.8
EV / EBITDA	-2.2
Price / Book	3.35
Price / Sales	7.73
DCF Value (model)	$-2.04
DCF Upside vs Price	-148.5%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$5.21M
Net Margin	-429.4%
Return on Equity	-99.7%
Debt / Equity	0.33
Current Ratio	2.27
Revenue Growth (YoY)	-10.5%
EPS Growth (YoY)	-85.1%
FCF Growth (YoY)	94.8%

Financial Health — source: SEC EDGAR
Altman Z-Score	-11.65 (distress)

Valuation vs Sector & Industry
Stock P/E	-38.8
Sector P/E (Healthcare)	21.0
Industry P/E (Medical Equipment)	31.7
vs Sector	-285.1%
vs Industry	-222.2%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	VANGUARD GROUP INC ($1.17M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Medical Equipment
CEO	Marc H. Hedrick
Employees	21
Country	US
IPO Date	2001-07-11

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.